Post-Transplantation Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplantation: Results of the Prospective Randomized HOVON-96 Trial in Recipients of Matched Related and Unrelated Donors

Cornelis N De Jong,Ellen Meijer,Katerina Bakunina,Erfan Nur,Marinus Van Marwijk Kooij,Marco R De Groot,Michel Van Gelder,Johan A Maertens,Jurgen H.E Kuball,Dries Deeren,Bronno Van Der Holt,Jan J Cornelissen,Annoek E.C Broers

doi:10.1182/blood-2019-124659

Post-Transplantation Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplantation: Results of the Prospective Randomized HOVON-96 Trial in Recipients of Matched Related and Unrelated Donors

Cornelis N De Jong, Ellen Meijer + Show 11 more

Open Access

https://doi.org/10.1182/blood-2019-124659

Copy DOI

Journal: Blood	Publication Date: Nov 13, 2019
Citations: 32

Affiliation: Erasmus MC Cancer Institute, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Isala, University Medical Center Groningen, Maastricht University, University Medical Center Utrecht, AZ Delta, Hovon

#Personal Fees #Post-transplant Cyclophosphamide + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Nur: Novartis Pharmaceuticals: Consultancy. Maertens:Cidara: Other: Personal fees and non-financial support; Gilead Sciences: Other: Grants, personal fees and non-financial support; Amplyx: Other: Personal fees and non-financial support; Merck: Other: Personal fees and non-financial support; Pfizer: Other: Grant and personal fees; Astellas Pharma: Other: Personal fees and non-financial support; F2G: Other: Personal fees and non-financial support. Deeren:Alexion, Amgen, Janssen, Roche, Sunesis, Takeda, Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding.

Full Text